ly3437943 retatrutide triple agonist glp-1 gip glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide (LY3437943) | MyBioSource

But thanks to liquid liposomal technology, glutathione avoids this breakdown and thus achieves maximum effectiveness

It's not necessary to analyze whether the medication caused the mood change or if other factors in life are responsible

The possibility is suggested that analogous maturational changes may contribute to differences in the way learning is accomplished in the newborn human brain and during later development

Adding a medication that stimulates GLP-1 receptors on C-cells, even if human C-cells respond minimally compared to rodent C-cells, represents an unacceptable theoretical risk in this population

Replacement of microglia in the aged brain reverses cognitive, synaptic, and neuronal deficits in mice

Komatsu, T., Uchida, K., Fujita, F., Zhou, Y